$5.43
2.86% yesterday
Nasdaq, Jun 27, 10:00 pm CET
ISIN
NL0015285941
Symbol
IMTX
Sector
Industry

Immatics N.V Stock price

$5.43
+0.50 10.14% 1M
-1.70 23.84% 6M
-1.68 23.63% YTD
-6.36 53.94% 1Y
-3.42 38.64% 3Y
-9.62 63.92% 5Y
-4.17 43.44% 10Y
-4.17 43.44% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.16 2.86%
ISIN
NL0015285941
Symbol
IMTX
Sector
Industry

Key metrics

Basic
Market capitalization
$660.0m
Enterprise Value
$-29.4m
Net debt
$-689.5m
Cash
$708.5m
Shares outstanding
121.6m
Valuation (TTM | estimate)
P/E
38.79 | negative
P/S
3.61 | 8.83
EV/Sales
negative | negative
EV/FCF
0.14
P/B
0.98
Financial Health
Equity Ratio
82.57%
Return on Equity
2.65%
ROCE
-6.15%
ROIC
-91.33%
Debt/Equity
0.03
Financials (TTM | estimate)
Revenue
$182.7m | $74.8m
EBITDA
$-30.9m | $-166.5m
EBIT
$-45.3m
Net Income
$17.8m | $-182.6m
Free Cash Flow
$-204.5m
Growth (TTM | estimate)
Revenue
188.32% | -59.07%
EBITDA
72.06% | -376.51%
EBIT
62.02%
Net Income
115.70% | -1,123.60%
Free Cash Flow
-1,270.91%
Margin (TTM | estimate)
Gross
-
EBITDA
-16.94% | -222.72%
EBIT
-24.78%
Net
9.76% | -244.28%
Free Cash Flow
-111.98%
More
EPS
$0.14
FCF per Share
$-1.68
Short interest
4.44%
Employees
618.00
Rev per Employee
$300.00k
Show more

Is Immatics N.V a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Immatics N.V Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Immatics N.V forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Immatics N.V forecast:

Buy
93%
Hold
7%

Financial data from Immatics N.V

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
183 183
188% 188%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 54 54
21% 21%
30%
- Research and Development Expense 174 174
25% 25%
95%
-31 -31
72% 72%
-17%
- Depreciation and Amortization 14 14
69% 69%
8%
EBIT (Operating Income) EBIT -45 -45
62% 62%
-25%
Net Profit 18 18
116% 116%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Immatics N.V directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immatics N.V Stock News

Neutral
GlobeNewsWire
28 days ago
Stafford , Texas and Tuebingen, Germany, May 31, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the presentation of expanded data from the ongoing Phase 1b clinical trial evaluating IMA203 PRAME cell therapy in heavily pretreated pat...
Neutral
GlobeNewsWire
about 2 months ago
Houston, Texas and Tuebingen, Germany, May 13, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended March 31, 2025.
Neutral
GlobeNewsWire
2 months ago
Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Societ...
More Immatics N.V News

Company Profile

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.

Head office Netherlands
CEO Harpreet Singh-Jasuja
Employees 618
Founded 2020
Website immatics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today